Navigation Links
BioMed Realty Trust Announces Tax Treatment of 2007 Distributions

SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the tax treatment of its 2007 distributions as follows:

Security Description: Common Stock

CUSIP: 09063H107

Ticker Symbol: BMR

Total Allocable

Record Payable Distribution to Taxable Ordinary

Date Date Per Share 2007 Dividend

12/29/2006 1/16/2007 $0.290000 $0.290000 $0.237498

3/30/2007 4/16/2007 $0.310000 $0.310000 $0.253877

6/29/2007 7/16/2007 $0.310000 $0.310000 $0.237089

9/28/2007 10/15/2007 $0.310000 $0.310000 $0.253877

Totals $1.220000 $1.220000 $0.982341


Record Payable Return of Long-Term Section 1250

Date Date Capital Capital Gain Gain

12/29/2006 1/16/2007 $0.052502 $0.000000 $0.000000

3/30/2007 4/16/2007 $0.056123 $0.000000 $0.000000

6/29/2007 7/16/2007 $0.056123 $0.016788 $0.009224

9/28/2007 10/15/2007 $0.056123 $0.000000 $0.000000

Totals $0.220871 $0.016788 $0.009224
Security Description: 7.375% Series A Cumulative Redeemable Preferred Stock
CUSIP: 09063H206

Ticker Symbol: BMR PR A

Total Taxable

Record Payable Distribution Allocable Ordinary

Date Date Per Share to 2007 Dividend

3/30/2007 4/16/2007 $0.455820 $0.455820 $0.455820

6/29/2007 7/16/2007 $0.455820 $0.455820 $0.432753

9/28/2007 10/15/2007 $0.460940 $0.460940 $0.460940

Totals $1.372580 $1.372580 $1.349513


Record Payable Return of Long-Term Section 1250

Date Date Capital Capital Gain Gain

3/30/2007 4/16/2007 $0.000000 $0.000000 $0.000000

6/29/2007 7/16/2007 $0.000000 $0.023067 $0.012674

9/28/2007 10/15/2007 $0.000000 $0.000000 $0.000000

Totals $0.000000 $0.023067 $0.012674

The distributions payable on January 15, 2008 to shareholders of record on December 31, 2007 are considered 2008 distributions for federal income tax purposes.

The company did not incur any foreign taxes during 2007. In addition, only for purposes of calculating alternative minimum taxable income under Section 55 of the Internal Revenue Code of 1986, as amended, the company apportions $0.002 per common share and Series A preferred share attributable to depreciation, each assuming a full year of ownership. Stockholders are encouraged to consult with their personal tax advisors as to their specific tax treatment of BioMed Realty Trust distributions.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 68 properties, representing 104 buildings with approximately 8.5 million rentable square feet, as well as approximately 1.9 million square feet of development in progress. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

CONTACT: Kent Griffin

Chief Financial Officer

(858) 485-9840

SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):